Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	0.3820 $	+6.02%	339,724
15/06/26	0.3603 $	-4.66%	493,374
12/06/26	0.3779 $	+0.64%	336,317
11/06/26	0.3755 $	+6.43%	540,087
10/06/26	0.3528 $	-3.61%	203,519

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3820USD

Average target price

1.500USD

Spread / Average Target

+292.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 16/06/2026 BST			5-day change	1st Jan Change
0.3820 ^USD	+6.02%		+4.37%	-25.10%

06-09	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
06-02	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT

Market Cap	15.52M 13.38M 12.32M 11.56M 21.71M 1.47B 21.94M 146M 56.7M 719M 58.25M 57.01M 2.49B	P/E Ratio 2026 *	-1.27x	P/E Ratio 2027 *	-6.37x
Enterprise Value	15.52M 13.38M 12.32M 11.56M 21.71M 1.47B 21.94M 146M 56.7M 719M 58.25M 57.01M 2.49B	EV / Sales 2026 *	3.03x	EV / Sales 2027 *	0.9x
Free-Float	86.69%	Yield 2026 *	-	Yield 2027 *	-

06-09	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
06-02	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
05-29	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
05-29	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
05-15	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
05-07	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
04-26	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
03-30	Scienture reports year end 2025 financial results and provides business update	RE
03-30	Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Scienture Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-11	Scienture Broadens Commercial Access for Rezenopy, Highest-Dose Fda-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching over 5,000 U.S. Institutions	CI
02-03	Scienture provides commercial update on Arbli(TM), the first FDA-approved ready-to-use oral suspension of losartan potassium	RE

14/08/25	Top Midday Decliners	MT
01/06/23	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
28/03/23	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
10/05/22	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
29/03/22	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

Scienture Holdings, Inc. Share Price

Stocks

SCNX

US80880X1046

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news : Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Course Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-09	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team	AQ
06-04	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC	AQ
06-02	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041	AQ
05-18	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion	AQ
05-15	Scienture Holdings: Q1 Earnings Snapshot	AQ

1 day	+6.02%
1 week	+4.37%
Current month	-7.51%
1 month	-5.21%
3 months	-15.67%
6 months	-30.55%
Current year	-25.10%

1 week	0.34	0.4
1 month	0.31	0.42
Current year	0.24	0.64
1 year	0.24	2.6
3 years	0.24	13.42
5 years	0.24	13.42
10 years	0.24	13.42

Date	Insider	Type	Main position	Quantity	% Market Cap.
18/09/24	Narasimhan Mani	Conversion	Director	2,927,538	167.2839%
18/09/24	Shankar Hariharan	Conversion	Chief Executive Officer	3,853,296	220.1831%
24/07/24	Hariharan Shankar	Other	Director	97,087	6.9035%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	+6.02%	+4.37%	-63.62%	-	15.52M
MCKESSON CORPORATION	+0.72%	+0.15%	+9.15%	+93.36%	91.96B
CARDINAL HEALTH, INC.	+0.58%	+7.08%	+40.21%	+149.56%	53.33B
SIGMA HEALTHCARE LIMITED	0.00%	+1.81%	-13.80%	+224.86%	22.86B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-0.80%	+0.19%	-9.47%	-25.68%	8.06B
HUADONG MEDICINE CO., LTD	-2.55%	+1.29%	-35.30%	-33.08%	7.33B
SINOPHARM GROUP CO. LTD.	-0.77%	-1.41%	-8.48%	-31.54%	6.76B
H. LUNDBECK A/S	-2.45%	-1.91%	+9.67%	+16.58%	6.3B
GALENICA AG	+0.54%	+0.89%	-2.03%	+17.84%	5.31B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-1.64%	+0.63%	-9.96%	-14.30%	3.53B
Average	-0.04%	+1.15%	-8.36%	+44.18%	20.55B
Weighted average by Cap.	+0.24%	+3.02%	+11.16%	+103.13%

	2026 *	2027 *
Net sales	5.12M 4.42M 4.07M 3.82M 7.17M 484M 7.24M 48.04M 18.72M 237M 19.23M 18.82M 822M	17.22M 14.84M 13.66M 12.83M 24.09M 1.63B 24.34M 161M 62.9M 797M 64.61M 63.24M 2.76B
Net income	-12.52M -10.79M -9.93M -9.33M -17.51M -1.18B -17.7M -117M -45.73M -580M -46.98M -45.98M -2.01B	-2.81M -2.43M -2.23M -2.1M -3.94M -266M -3.98M -26.39M -10.28M -130M -10.56M -10.34M -452M
Net Debt	-	-